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ABSTRACT 
Background: Many episodes of worsening of heart failure (HF) are treated by increasing oral 
therapy or intravenous treatment in the community or emergency department (ED), without 
hospital admission. We studied the frequency and prognostic importance of these episodes of 
worsening in PARADIGM-HF.   
Methods and Results: Outpatient intensification of HF therapy (IT) was added to an 
expanded composite outcome with ED visits, HF hospitalizations (HFh) and cardiovascular 
deaths. Examining first non-fatal events, 361/8399 patients (4.3%) had IT without a 
subsequent event (i.e. ED visit/HFh) within 30 days; 78/8399 (1.0%) had an ED visit without 
prior IT or a subsequent event within 30 days; and 1107/8399 (13.2%) had HFh without a 
preceding event. The risk of death (compared with “no event” patients) was similar after each 
manifestation of worsening - IT: HR=4.8(95%CI 3.9-5.9); ED visit: 4.5(3.0-6.7); HFh: 
5.9(5.2-6.6). The expanded composite added 14% more events and shortened time to accrual 
of a fixed number of events. The benefit of sacubitril/valsartan over enalapril was similar to 
the primary outcome for the expanded composite (HR 0.79, 0.73-0.86) and was consistent 
across the components of the latter.  
Conclusion: Focusing only on HFh underestimates the frequency of worsening and the 
serious implications of all manifestations of worsening. For clinical trials conducted in an era 
of heightened efforts to avoid HFh, inclusion of episodes of outpatient treatment 
intensification (and ED visits) in a composite outcome adds an important number of events 
and shortens the time taken to accrue a target number of endpoints in an event-driven trial. 
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Clinical Trial Registration Information—www.clinicaltrials.gov. Identifier: NCT01035255. 
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INTRODUCTION 
Worsening of symptoms and signs leading to hospital admission is an important event for 
patients with heart failure as not only is it an unpleasant experience but it is also a marker of 
heightened subsequent risk of re-admission and death.1,2  Hospital admissions also place an 
economic burden on patients and their families or caregivers, health services and society 
more generally.3,4  For these reasons, heart failure hospitalization has long been considered 
an important endpoint in clinical trials and more recently it has become a measure of the 
quality of care in the USA with linkage of reimbursement to readmission rates within 30 days 
of discharge.5-9  Many episodes of worsening of heart failure are, however, treated by 
augmentation of oral therapy in the community or even the use of short-term intravenous 
treatment.  Some episodes may also lead to an emergency department (ED) visit without 
subsequent admission to hospital.10-13  Management of heart failure in the community or in 
non-ward-based hospital settings has also been encouraged recently by many organizations as 
a result of the reimbursement changes mentioned above.6-9,14  Little is known, however, 
about the frequency of, and prognostic importance of, such non-hospitalized episodes of 
worsening.15  We have studied the occurrence and significance of these episodes in the 
Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and 
Morbidity in Heart Failure Trial (PARADIGM-HF).16-18  We have also investigated the 
potential value of such events in an expanded composite outcome which might be of use as 
an endpoint in future clinical trials. 
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METHODS 
Patients 
The background and results of PARADIGM-HF (www.clinicaltrials.gov. identifier: 
NCT01035255) have been published.16-18 The Ethics Committee of each of the 1043 
participating institutions (in 47 countries) approved the protocol. All patients gave written, 
informed consent. Briefly, PARADIGM-HF was a randomized, double-blind, and 
prospective comparison of the angiotensin-receptor-neprilysin inhibitor (ARNI) 
sacubitril/valsartan (formerly known as LCZ696) with enalapril in patients with chronic heart 
failure. Eligibility requirements at screening included an age of at least 18 years, New York 
Heart Association (NYHA) functional class II-IV symptoms, and an left ventricular ejection 
fraction of 40% or less and guideline-recommended therapy.  
 
Trial outcomes 
The primary outcome of PARADIGM-HF was the composite of cardiovascular death or heart 
failure hospitalization. Additional pre-specified exploratory endpoints included ED visits and 
outpatient intensification of heart failure therapy, collected by means of check box questions 
(yes/no) asked at each study visit. Three questions were asked in relation to outpatient 
intensification of heart failure therapy: was the dose of diuretics increased and sustained for a 
month (yes/no), was intravenous treatment given for heart failure (yes/no) or was a new drug 
added for the treatment of worsening heart failure (yes/no)? If any of these were answered in 
the affirmative the patients was prospectively considered to have had outpatient 
intensification of heart failure therapy. 
 
We examined the characteristics of and subsequent survival of patients having a first event of 
each type and survival after each event type. In this analysis, if patients had an ED visit or 
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were hospitalized within 30 days after intensification of therapy, they were classified as either 
an ED visit or heart failure hospitalization, respectively. If patients were hospitalized within 
30 days after an ED visit they were classified as a heart failure hospitalization and not an ED 
visit. The reference group consisted of patients who had none of these events during the trial 
(“no event” group). We also used this analysis to estimate the reduction in time taken to 
accrue a certain number of composite events, comparing the expanded composite 
(cardiovascular death, heart failure hospitalization, ED visit or outpatient intensification of 
therapy) with the narrowest (i.e. the primary composite endpoint of cardiovascular death or 
heart failure hospitalization) using a time-to-first event analysis. In a sensitivity analysis, we 
used seven instead of thirty days as the interval separating events. 
 
To examine the number of unique events added by considering outpatient intensification of 
therapy and ED visits, we also categorized patients into three mutually exclusive groups for a 
first non-fatal event (i.e. without any of the listed non-fatal events preceding the event of 
interest) or cardiovascular death: those having outpatient intensification of heart failure 
therapy (without a subsequent ED visit or heart failure hospitalization), those having an ED 
visit (without a subsequent heart failure hospitalization) and those having a heart failure 
hospitalization as their first non-fatal event.  
 
We also examined the effect of sacubitril/valsartan compared with enalapril on the expanded 
composite outcome and its components.  
 
Statistical analysis 
Baseline characteristics were compared using the Kruskal Wallis test for continuous variables 
and the chi square test for categorical variables. The association between a first event and 
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subsequent mortality was evaluated with the use of Kaplan-Meier estimates and examined in 
a Cox regression model with the “no event” group used as reference. The relative hazard of 
death following a first event was examined in a Cox proportional hazards model where an 
indicator of a patient’s first event type was entered into the model as a time-updated covariate 
(with follow up time starting at randomization) and adjusted for the effect of randomized 
therapy and region and then with the addition of the following baseline variables: : age, sex, 
race, systolic blood pressure, heart rate, body mass index (BMI), serum creatinine, left 
ventricular ejection fraction (LVEF), N-terminal pro-BNP (NTproBNP), New York Heart 
Association (NYHA) class, ischemic etiology, hypertension, diabetes, atrial fibrillation, prior 
heart failure, myocardial infarction, stroke, prior implantable cardioverter-defibrillator, and 
cardiac resynchronization therapy. Hazard ratios (HR), 95% confidence intervals (CI), and 
two-sided P values were calculated with the use of the Cox models. All analyses were 
performed using Stata version 14 (Stata Corp. College Station, Texas, USA). A p value of 
<0.05 was considered significant. 
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RESULTS 
Of the 8399 patients randomized, 1124 (13.4%) had outpatient intensification of therapy, 250 
(3.0%) had an ED visit, 1195 (14.2%) were hospitalized for worsening heart failure, 1251 
(14.9%) died from a cardiovascular cause, and 1546 (18.4%) died from any cause.  
Among all randomized patients, 763 (9.1%) died from a cardiovascular cause without prior 
worsening heart failure hospitalization, ED visit or intensification of therapy.  
 
Examining first non-fatal events, 361 patients (4.3%) had intensification of therapy without a 
subsequent ED visit, hospital admission for heart failure or cardiovascular death within 30 
days; 78 (1.0%) had an ED visit but no prior intensification of therapy or subsequent hospital 
admission for worsening heart failure or cardiovascular death within 30 days; and 1107 
patients (13.2%) had worsening heart failure requiring hospitalization without a preceding 
ED visit or intensification of therapy.  
 
Examining mutually exclusive first non-fatal events, 223 patients (62% of 361) having 
intensification of therapy and 52 patients (67% of 78) experiencing an ED visit did not have a 
subsequent non-fatal heart failure event during the trial period or die from a CV cause. The 
numbers not experiencing a non-fatal heart failure event or dying from any cause were 203 
(56% of 361) and 48 (62% of 78) for those having intensification of therapy and ED visit 
respectively. Therefore, these two outcomes added 278 unique events (13.7%) to the 2031 
primary composite endpoints (cardiovascular death or heart failure hospitalization) accrued in 
PARADIGM-HF.   
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Baseline characteristics 
The baseline characteristics of patients with the different first manifestations of heart failure 
worsening, experiencing cardiovascular death or having no event are shown in Table 1.  
Patients with any manifestation of worsening were older, less likely to be female and more 
likely to have comorbidity. Patients with any manifestation of worsening also had higher 
B-type natriuretic peptide levels, worse NYHA functional class, were more commonly 
treated with diuretics, digoxin, a defibrillating device and cardiac resynchronization therapy 
and more frequently had a history of pre-randomization heart failure hospitalization. 
 
Different manifestations of worsening and subsequent survival 
Figure 1 shows the rate of death and Table 2 the unadjusted and adjusted risks of death 
subsequent to intensification of therapy, an ED visit or a heart failure hospitalization, 
compared with patients who did not experience any manifestation of worsening. Overall, 
14% of patients without any report of worsening died during the trial.  The proportion dying 
was 32%, 31% and 37%, respectively, for those having intensification of therapy, 
experiencing an ED visit or being admitted to hospital with worsening heart failure. Most 
deaths were attributed to cardiovascular causes.  
 
The risk of death (compared with “no event” patients after adjustment for treatment and 
region only) was similar after each of the three manifestations of worsening - intensification 
of therapy: HR 5.2 (95% CI, 4.2-6.3); ED visit: 4.5 (3.0-6.7); hospitalization for worsening 
heart failure: 6.1 (5.4-6.8). Even after adjustment, the risk of death remained three to five 
times higher in patients experiencing some manifestation of worsening, compared with those 
who did not. When those patients who had only either a hospitalization for heart failure, ED 
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visit or intensification of therapy were analyzed i.e. they experienced that event type only, the 
associations between each of the event types and mortality were unchanged (Table 2). 
Using a seven day rather than thirty day interval between events (to define separate events) 
did not change the results (Appendix). 
We conducted a sensitivity analysis by baseline diuretic status. In the patients not taking a 
diuretic (N=1661) at baseline, the risk of death was higher in those who started a diuretic 
during the trial (N=443, all-cause mortality=20.5%) compared to those who did not start a 
diuretic during the trial (N=1218, all-cause mortality=12.6%). Of those taking a diuretic at 
baseline, the risk of death in those who were taking the equivalent of <40mg of furosemide at 
baseline was 16.4% and in those taking e40mg furosemide equivalent the risk was 21.0%. 
The association between each of the outcomes (HF hospitalization, ED visit for HF, or 
intensification of therapy for HF) and the risk of all-cause mortality was similar regardless of 
the baseline dose of furosemide equivalent. (Supplemental Table 1). Of those who 
experienced an intensification of heart failure therapy that was due to an increase in diuretic 
dose for over one month, the risk of death was higher in those who had an increase in dose 
that was e40mg of furosemide equivalent compared to <40mg furosemide equivalent 
(Supplemental Table 2). 
We also examined which medications were added for the treatment of worsening heart failure 
(N=62). This was a diuretic in 23 (37%), a MRA in 17 (27%), a beta-blocker in 9 (15%), an 
ACEI/ARB in 8 (13%) and other drugs (digoxin in 2; unspecified in 3) in 5(8%). 
The association between each manifestation of worsening HF and subsequent all-cause 
mortality was highest for intravenous treatment given for HF: dose of diuretics increased and 
sustained for a month HR= 3.2 (95%CI 2.2-5.0), intravenous treatment for HF 
(HR=7.3[95%CI 5.5-9.6]), and new drug added for the treatment of worsening HF 
(HR=3.7[95%CI 2.3-5.8]). 
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Expanded composite outcomes and time to accrual of a target number of events 
Figure 2 shows the impact of adding intensification of therapy and ED visits to the primary 
composite outcome (cardiovascular death or heart failure hospitalization) of 
PARADIGM-HF. As can be seen at one, two and three years of follow-up, an additional 177, 
248 and 269 patients, respectively, had experienced a first event contributing to the expanded 
composite outcome compared with the primary endpoint, an increment in events of around 
14% overall. The one and two year Kaplan-Meier event rates for the primary endpoint were 
14.2% and 24.0%, respectively, compared with 16.5% and 27.5%, respectively, for the 
expanded composite. The time taken to accrue 1000 patients with an event using the primary 
endpoint was 11 months (338 days) compared with 9 months (280 days) for the expanded 
composite. 
 
Effect of sacubitril/valsartan on primary composite outcome and expanded composite 
Figure 3 shows the effect of sacubitril/valsartan on the primary composite outcome of 
PARADIGM-HF as well as the expanded composite outcome and the components of each of 
these.  
Sacubitril/valsartan was superior to enalapril in reducing the risk of the primary composite 
outcome (HR 0.80, 0.73-0.87), death from cardiovascular causes (HR 0.80, 0.71-0.89), and 
hospitalization for heart failure (HR 0.79, 0.71-0.89). 
As can be seen from Figure 4, the benefit of sacubitril/valsartan over enalapril was similar for 
the expanded composite (HR 0.79, 0.73-0.86) and the effect of sacubitril/valsartan was 
consistent in relation to the additional components of this expanded composite. This effect of 
sacubitril/valsartan compared with enalapril on the expanded composite was also consistent 
across all subgroups e.g. age, sex, race, region, medical history (data not shown). 
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DISCUSSION 
Our findings are relevant to both clinical practice and the conduct of future clinical trials in 
HF-REF.  
Firstly, as expected, we found that worsening leading to outpatient intensification of medical 
therapy is common in patients with HF-REF but more surprisingly was associated with an 
elevation in the risk of subsequent death similar to that seen following hospital admission. 
Focusing only on heart failure hospitalization therefore underestimates the frequency of 
clinical worsening and fails to recognize that all manifestations of worsening have such 
serious implications.  
 
For clinical trials conducted in an era of heightened efforts to avoid hospitalization in patients 
with heart failure, inclusion of episodes of outpatient intensification of medical therapy (and 
ED visits) in a composite outcome adds an important number of events (an increment of 14% 
in PARADIGM-HF) and would shorten the time taken to accrue a target number of endpoints 
in an event-driven trial. Because sacubitril/valsartan had a consistent effect on all 
manifestations of worsening, the benefit of sacubitril/valsartan over enalapril on the expanded 
composite outcome was similar to that on the primary endpoint in PARADIGM-HF. 
Therefore, use of this expanded composite could have resulted in earlier termination of the 
trial without any loss of sensitivity to the effect of the investigational treatment.  
 
Although everyday clinical experience indicates that augmentation of oral therapy and even 
supplementation with intravenous treatment is common in patients with heart failure, we have 
been unable to find any report of how frequently such interventions occur in usual clinical 
practice. Asking questions about augmentation of treatment at each study visit, we found that 
13.4% of patients had intensification of therapy and that two thirds of these episodes were 
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followed by an ED visit or heart failure hospitalization within 30 days. However, it should be 
noted that the majority of patients in PARADIGM-HF were in NYHA functional class I 
(4.6%) or II (70.5%) after the active run-in period and the proportion requiring intensification 
of therapy might be much greater in patients with more severe symptoms at baseline. The 
more important finding is that, even if augmentation of therapy was not followed by an ED 
visit or admission, it was associated with a four-fold higher adjusted risk of subsequent death. 
Therefore, although these episodes were identified only by investigators checking “yes” in 
response to questions (and were not adjudicated), they were an ominous occurrence and 
arguably should be both a treatment target (to reduce their incidence) and a measure of 
outcome (e.g. as part of a composite “worsening” endpoint). Not only were these episodes 
frequent and serious but they were also responsive to the experimental treatment intervention 
in PARADIGM-HF, further supporting their use in an expanded composite endpoint (see 
below). 
 
By contrast, ED visits were uncommonly reported (in 3% of patients) and were also 
frequently followed by heart failure hospitalization within 30 days (in 69% of cases). We 
believe that our investigators did not report ED visits leading directly to admission to hospital 
as separate events (as admission was itself an endpoint). In most countries the vast majority 
of ED attendances with heart failure lead to admission and discharge directly from the ED is 
very uncommon. It is likely that this explains the small proportion of such events in 
PARADIGM-HF. An isolated ED visit was also associated with a four to five-fold higher 
subsequent mortality (compared with having no episode of worsening), and this heightened 
risk persisted after adjustment for other prognostic variables.  
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From a clinical practice perspective, we believe that there are two important messages from 
our findings. Firstly, intensification of outpatient therapy should be carefully documented and 
should prompt a review of affected patients. Often the care of patients is shared and may be 
disjointed. Therapy may be changed by a primary care practitioner, nurse specialist, internist 
or other specialist (during a hospital clinic attendance for another reason) or by a cardiologist. 
It is easy to overlook such changes yet they identify a patient at high risk. Should there be a 
system in place to identify these changes? Such changes should prompt review of the patient 
– have all disease modifying drugs been used (e.g. could a mineralocorticoid receptor 
antagonist or digoxin be added)? Have all life-saving devices been considered (e.g. CRT and 
an ICD)? Has the patient progressed to the point of being considered for a ventricular assist 
device or transplantation? 
 
Our findings are potentially important from a clinical trials perspective as well. Although 
most episodes of intensification of outpatient therapy and ED visits were followed by a heart 
failure hospitalization within 30 days, around one third were not. Therefore, expanding the 
primary composite outcome (heart failure hospitalization or cardiovascular death) used in 
PARADIGM-HF and other recent studies to include these additional components has two 
consequences. Firstly, doing so adds unique events (an additional 14% overall). Secondly it 
shortens the time to accrual of any given number of “worsening events”. This is because 
intensification of outpatient therapy and ED visits often occur before and therefore earlier 
than a heart failure hospitalization. These effects have the potential to reduce sample size and 
duration of follow-up (or increase power if sample-size is maintained) although these 
advantages can only be realized if the additional components of the composite (and thus the 
overall expanded composite) are as sensitive to the effects of treatment as heart failure 
hospitalization and cardiovascular death are (although these do not always respond equally to 
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treatment). We found that this was the case for sacubitril/valsartan, with as similar treatment 
effect on all components of the expanded composite outcome examined, but this might not 
necessarily be so for all treatments. This expanded composite may be especially relevant 
today given the intensive efforts to reduce admissions to hospital for heart failure in the USA 
(and may “even out” the rates of worsening across geographic regions by including all 
manifestations of worsening irrespective of how or where they are managed). In addition, as 
event rates have declined as a result of the cumulative benefit of effective treatments, trials in 
HF-REF have required larger and larger sample sizes increasing their complexity and cost, 
and making the development of new treatments less attractive and affordable than previously. 
The only other way to accrue sufficient events is to lengthen follow-up but this too leads 
higher costs and less precision due to treatment discontinuation and patient loss to follow-up. 
Our findings suggest that use of the expanded composite described has the potential to reduce 
sample-size and duration of follow-up by a modest amount and we believe that its use might 
be considered in future trials. We know of only a few trials in patients with chronic heart 
failure and a reduced ejection fraction which used non-hospitalized events as part of their 
primary endpoint and each required intravenous therapy as part of the definition of these 
events.15, 19-21 In the Valsartan Heart Failure Trial (Val-HeFT), administration of intravenous 
inotropic or vasodilator drugs for four hours or more without hospitalization was a 
component of the composite co-primary outcome.19 Of the 1524 first events, there were only 
10 non-hospitalized treatment events compared with 801 heart failure hospitalizations, 42 
resuscitated cardiac arrests and 671 deaths. The Multicenter Automatic Defibrillator 
Implantation with Cardiac Resynchronization trial (MADIT-CRT) included outpatient events 
requiring the use of intravenous decongestive therapy.15 Of first events, 52 were out-patient 
events, 331 in-patient treatment events and 78 were deaths. The smaller proportion of 
out-patient events in these trials presumably reflects the requirement for intravenous therapy 
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(as opposed to augment or oral or intravenous therapy) and, perhaps, changing practice since 
publication of Val-HeFT. The individual contribution of non-hospitalized intravenous therapy 
to the overall primary outcome was not described separately in the Comparison of Medical 
Therapy, Pacing, and Defibrillation in Heart Failure trial (COMPANION) and the 
Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular 
Block trial (BLOCK HF).20, 21 
Our report has some limitations. Not all of the analyses reported were pre-specified. The ED 
visits and intensification of oral therapy were not adjudicated (whereas heart failure 
hospitalizations and deaths were) and we do not have details of the drugs added to treat 
worsening heart failure. For the increase in diuretic dose component of the “intensification of 
therapy” endpoint, we required the increased to be sustained for at least a month, making this 
a relatively stringent component. 
In conclusion, focusing only on heart failure hospitalization underestimates the frequency of 
clinical worsening and fails to recognize that other manifestations of worsening seem to have 
serious prognostic implications. If our findings are valid, they argue for systematic approach 
in clinical practice to document episodes of non-hospitalized worsening and their occurrence 
should prompt a review of affected patients. For clinical trials conducted in an era of 
heightened efforts to avoid hospitalization in patients with heart failure, inclusion of episodes 
of outpatient intensification of therapy (and ED visits) in a composite outcome adds a modest 
but important number of events and shortens the time taken to accrue a target number of 
endpoints in an event-driven trial. These additional events seem to be sensitive to the actions 
of effective therapy, at least as demonstrated with sacubitril valsartan. 
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LEGENDS 
Figure 1 
Mortality (%) after a first event or in patients with no event. 
 
Figure 2 
Impact of adding emergency department visits and outpatient intensification therapy as 
additional components of a composite heart failure outcome. 
 
Figure 3 
Kaplan-Meier curves for primary endpoint (A) and expanded composite (B), according to 
treatment group. 
 
Figure 4 
 
Effect of sacubitril/valsartan versus enalapril for each outcome.
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Table 1 
The baseline characteristics of patients with different first manifestations of heart failure worsening, or none, or experiencing cardiovascular 
death 
 
None of event 
Hospitalization 
for HF 
Emergency 
department visit 
for HF 
Intensification of 
HF   
therapy 
Cardiovascular  
    death 
P value 
N (%) 6090 (73%) 1107 (13%) 78 (1%) 361 (4%) 763 (9%) 
 
Age (year) 63±11 64±11 66±12 65±11 64±12 <0.001 
Sex (female) (%) 1410 (23%) 212 (19%) 16 (21%) 56 (16%) 138 (18%) <0.001 
Race (%) 
      
 White  4016 (66%) 749 (68%) 43 (55%) 287 (80%) 449 (60%) 
<0.001 
 Black 285 (5%) 82 (7%) 6 (8%) 17 (5%) 38 (5%) 
 Asian  1097 (18%) 188 (17%) 18 (23%) 28 (8%) 178 (23%) 
 Other 692 (11%) 88 (8%) 11 (14%) 29 (8%) 98 (13%) 
Region (%) 
      
 North America 365 (6%) 124 (11%) 13 (17%) 73 (20%) 27 (4%) 
<0.001 
 Latin America 1091 (18%) 142 (13%) 13 (17%) 39 (11%) 148 (19%) 
 Western Europe  
 and other 
1516 (25%) 275 (25%) 13 (17%) 111 (31%) 136 (18%) 
 Central Europe 2028 (33%) 384 (35%) 21 (27%) 110 (31%) 283 (37%) 
 Asia 1090 (18%) 182 (16%) 18 (23%) 28 (8%) 169 (22%) 
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Systolic blood pressure  
(mmHg) 
122±15 121±16 118±14 120±16 122±16 0.084 
Heart rate  
(beats/min) 
72±12 74±13 74±13 72±13 73±12 <0.001 
Body mass index (kg/m2)  28±5 29±6 27±6 29±6 27±6 <0.001 
Serum creatinine  
(mg/dl) 
1.1±0.3 1.2±0.3 1.2±0.3 1.2±0.3 1.2±0.3 <0.001 
Clinical features  
of heart failure       
Left ventricular  
Ejection Fraction (%) 
30±6 29±7 28±7 30±6 29±7 <0.001 
Median BNP (pg/ml) (IQR) 
227  
(142-407) 
365  
(195-723) 
290  
(167-528) 
286  
(176-560) 
369  
(206-689) 
<0.001 
Median NT-proBNP (pg/ml) (IQR) 
1438  
(819-2737) 
2367  
(1208-5154) 
1894  
(1103-3319) 
1923  
(1047-3722) 
2456  
(1260-5189) 
<0.001 
NYHA functional  
class (%)       
 I 309 (5%) 33 (3%) 7 (9%) 11 (3%) 29 (4%) 
<0.001 
 II 4399 (72%) 736 (67%) 50 (64%) 249 (69%) 485 (64%) 
 III 1332 (22%) 322 (29%) 21 (26%) 100 (28%) 243 (32%) 
 IV 38 (0.6%) 15 (1.4%) 0 (0%) 1 (0.3%) 6 (0.8%) 
Ischemic etiology (%) 3593 (59%) 669 (60%) 44 (56%) 227 (63%) 503 (66%) 0.004 
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Medical history (%) 
      
Hypertension  4252 (70%) 824 (74%) 59 (76%) 268 (74%) 537 (70%) 0.012 
Diabetes 1939 (32%) 492 (44%) 36 (46%) 162 (45%) 278 (36%) <0.001 
Atrial fibrillation 2123 (35%) 484 (44%) 34 (44%) 163 (45%) 287 (38%) <0.001 
Prior Heart failure  
hospitalization 
3663 (60%) 822 (74%) 53 (68%) 262 (73%) 474 (62%) <0.001 
Myocardial infarction 2544 (42%) 521 (47%) 27 (35%) 182 (50%) 360 (47%) <0.001 
Stroke 479 (8%) 115 (10%) 12 (15%) 43 (12%) 76 (10%) 0.001 
Treatment  
at randomization       
Prior use of ACE inhibitor 4744 (78%)  853 (77%) 60 (77%) 288 (80%) 587 (77%) 0.814 
Prior use of ARB  1362 (22%) 259 (23%) 19 (24%) 75 (21%) 177 (23%) 0.817 
Diuretics 4769 (78%) 979 (88%) 63 (81%) 307 (85%) 620 (81%) <0.001 
Digitalis 1755 (29%) 381 (34%) 27 (35%) 110 (31%) 266 (35%) <0.001 
Beta-blocker 5700 (94%) 1013 (92%) 69 (89%) 338 (94%) 691 (91%) 0.002 
Mineralocorticoid  
antagonist 
3390 (56%) 634 (57%) 39 (50%) 189 (52%) 419 (55%) 0.414 
Implantable  
cardioverter-defibrillator 
840 (14%) 230 (21%) 15 (19%) 97 (27%) 61 (8%) <0.001 
Cardiac resynchronization  
therapy 
383 (6%) 110 (10%) 7 (9%) 48 (13%) 26 (3%) <0.001 
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Table 2 
Risk of all-cause mortality following a hospitalization heart failure, emergency department visit for heart failure, and intensification of 
therapy for heart failure using a Cox model with event type as the 1st event experienced and the only event experienced in a time-updated 
covariate  
  None of the events Hospitalization for HF 
Emergency 
department visit for 
HF 
Intensification of HF  
therapy  
Each event as the 1st event experienced in a 
time updated model (Hazard Ratio (95% CI))     
Adjusted for randomized treatment and region 1 6.1 (5.4-6.8) 4.5 (3.0-6.7) 5.2 (4.2-6.3) 
Adjusted for randomized treatment, region and 
baseline covariates * 
1 5.3 (4.7-6.0) 3.3 (2.2-5.0) 4.6 (3.7-5.6) 
     
Each event as the only event experienced in a 
time updated model (Hazard Ratio (95% CI)) 
    
Adjusted for randomized treatment and region 1 5.8 (5.1-6.5) 4.1 (2.6-6.5) 4.5 (3.6-5.7) 
Adjusted for randomized treatment, region and 
baseline covariates * 
1 5.0 (4.4-5.7) 2.9 (1.9-4.6) 4.2 (3.3-5.3) 
* Adjusted for: age, sex, race, systolic blood pressure, heart rate, body mass index (BMI), serum creatinine, left ventricular ejection fraction (LVEF), 
N-terminal pro-BNP (NTproBNP), New York Heart Association (NYHA) class, ischemic etiology, hypertension, diabetes, atrial fibrillation, prior 
heart failure, myocardial infarction, stroke, prior implantable cardioverter-defibrillator, and cardiac resynchronization therapy. 
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Figure 1  Rate of death per 100 patient years after a first event or in patients with no event 
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Figure 2 
Impact of adding “outpatient intensification therapy” and “emergency department visits” as extra components to the primary composite outcome 
of cardiovascular death or heart failure hospitalization 
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Figure 3 
Kaplan-Meier curves for the primary composite endpoint (A) and the expanded composite (B), according to treatment group. 
(HR and corresponding p value are from the Cox model adjusted for region) 
 
  
Hazard ratio: 0.80 (95% CI, 0.73-0.87)   
P < 0.001 
Hazard ratio: 0.79 (95% CI, 0.73-0.86)   
P < 0.001 
A B 
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Figure 4 
Effect of sacubitril/valsartan versus enalapril for different outcomes 
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Supplemental Table 1  
Mortality (%) according to baseline diuretics dose 
 
 
No diuretic at baseline Other diuretics 
Low dose loop diuretic 
(<40mg furosemide 
equivalent*) 
High dose loop diuretic  
(e40mg furosemide equivalent*) 
 
(N=1661) (N=1324) (N=1620) (N=3794) 
         
All cause death 244 (14.7%) 239 (18.1%) 265 (16.4%) 798 (21.0%) 
CV death 199 (12.0%) 205 (15.5%) 215 (13.3%) 632 (16.7%) 
non-CV death 45 (3.1%) 34 (3.0%) 50 (3.6%) 166 (4.4%) 
          
* 1mg bumetanide= 40mg furosemide and 20mg torasemide= 40mg furosemide 
 
 
 
 
 
 
 
 
 Supplemental Table 2  
Risk of all-cause mortality following a hospitalization heart failure, emergency department visit for heart failure, and intensification of 
therapy for heart failure using a Cox model with event type as the 1st event experienced and the only event experienced in a 
time-updated covariate according to baseline loop diuretic dose 
 
 
No event 
Heart failure  
hospitalization 
Emergency  
department visit 
Intensification  
of therapy 
Each event as the 1st event experienced in a time 
updated model (Hazard Ratio (95% CI)) 
Adjusted for randomized treatment, region and baseline 
covariates* 
    
Low dose loop diuretic (<40mg furosemide 
equivalent**) 
(N=1620) 
1 
5.7 
(4.2-7.8) 
1.6 
(0.2-11.5) 
4.1 
(2.6-6.6) 
High dose loop diuretic (e40mg furosemide 
equivalent**) 
(N=3794) 
1 
5.0 
(4.2-5.9) 
3.6 
(2.1-6.1) 
5.4 
(4.1-7.1) 
Other diuretic 
(N=1324) 
1 
5.8 
(4.2-8.0) 
4.6 
(1.9-10.7) 
3.2 
(4.2-6.1) 
* Adjusted for: age, sex, race, systolic blood pressure, heart rate, body mass index (BMI), serum creatinine, left ventricular ejection 
fraction (LVEF), N-terminal pro-BNP (NTproBNP), New York Heart Association (NYHA) class, ischemic etiology, hypertension, 
diabetes, atrial fibrillation, prior heart failure, myocardial infarction, stroke, prior implantable cardioverter-defibrillator, and cardiac 
resynchronization therapy. 
** 1mg bumetanide= 40mg furosemide and 20mg torasemide= 40mg furosemide 
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